Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies
about
Natural killer T (NKT) cells accelerate Shiga toxin type 2 (Stx2) pathology in mice.Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody.Shiga toxin type-2 (Stx2) induces glutamate release via phosphoinositide 3-kinase (PI3K) pathway in murine neuronsPretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality.Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.Production and characterization of protective human antibodies against Shiga toxin 1Comparison of Shiga toxin production by hemolytic-uremic syndrome-associated and bovine-associated Shiga toxin-producing Escherichia coli isolates.Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice.A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.Activation of the Classical Mitogen-Activated Protein Kinases Is Part of the Shiga Toxin-Induced Ribotoxic Stress Response and May Contribute to Shiga Toxin-Induced Inflammation.Humoral immune responses to Shiga-like toxins and Escherichia coli O157 lipopolysaccharide in hemolytic-uremic syndrome patients and healthy subjectsPatients with haemolytic uraemic syndrome caused by Escherichia coli O157: absence of antibodies to Vero cytotoxin 1 (VT1) or VT2.In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2.Selective Evolution of Ligands by Exponential Enrichment to Identify RNA Aptamers against Shiga Toxins.Differences in Ribosome Binding and Sarcin/Ricin Loop Depurination by Shiga and Ricin HolotoxinsConstruction and characterization of an isogenic slt-ii deletion mutant of enterohemorrhagic Escherichia coli.Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2.Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells.Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications.Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis.Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cellsIsogenic lysogens of diverse shiga toxin 2-encoding bacteriophages produce markedly different amounts of shiga toxin.Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration.Comparison of Shiga-like toxin I B-subunit expression and localization in Escherichia coli and Vibrio cholerae by using trc or iron-regulated promoter systemsEffects of Shiga toxin type 2 on a bioengineered three-dimensional model of human renal tissue.Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variantsA system for production and rapid purification of large amounts of the Shiga toxin/Shiga-like toxin I B subunit.Expression and purification of Shiga-like toxin II B subunits.Translocation of Shiga toxin across polarized intestinal cells in tissue culture.Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strainsMaturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cellsMonoclonal antibodies and toxins--a perspective on function and isotype.Shiga toxin 2-induced intestinal pathology in infant rabbits is A-subunit dependent and responsive to the tyrosine kinase and potential ZAK inhibitor imatinibAlternate routes for drug delivery to the cell interior: pathways to the Golgi apparatus and endoplasmic reticulumMitomycin immunoblot colony assay for detection of Shiga-like toxin-producing Escherichia coli in fecal samples: comparison with DNA probes.Adherence of Escherichia coli O157:H7 mutants in vitro and in ligated pig intestines.A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli.The interactions of human neutrophils with shiga toxins and related plant toxins: danger or safety?Ribosome-inactivating proteins: potent poisons and molecular tools.
P2860
Q30300135-9CEC6CCE-0C32-4EF7-85BC-C842F280E270Q30481790-5BC27A56-5B04-4F81-A2E7-0D97F77DF0C3Q30657658-5AB38D79-1D5A-4F08-B536-4E31192D914EQ33331011-934B7A42-7BE6-485F-AE83-3CF9E8DC9870Q33340641-F3DCAEDC-9536-4633-96E8-45BA83C225B4Q33344261-BD2AB67E-793C-4A71-9F56-1445FC3D9452Q33346383-B45ECBCC-2BEB-4043-804C-309CD5DF2B70Q33401560-B963C246-6B95-4EEE-AAD1-F5DD1F284EFCQ33410645-1DC31769-54A2-484D-86E5-726B97CE0AD5Q33418526-089DB3B1-92D4-4528-AFC6-0B15C4ACF1B7Q33426863-FA9A8504-CDE5-4A7C-A57D-524F3FD12355Q33491823-5638453A-1942-48B0-8EE6-0F6E0FCB05C4Q33493218-1EFB3763-9E17-404E-82BF-C75FB1E95E23Q33545441-644E16B7-686C-4054-AA76-07412F16D854Q33563140-AD892367-4E73-46A5-AEDD-1DE0E1BBC403Q33612042-1C445EC1-97BE-428D-A0E6-30C2F1B45110Q33754052-FDC37ED5-091D-41DF-9870-9A67CCE7A95BQ33877305-5CDA6615-1013-4BBB-8D81-E85C8F3271CDQ33883354-5CFB94C6-B743-4A25-8ECD-C078D11E6010Q33946874-471F4262-31DB-49D4-B5DF-C9A3E2A73704Q34000714-91BED20F-9593-43A1-B992-ED761E1E10EEQ34002866-3F02AC7A-31F1-4B3D-8B3C-AC5B3715ECD5Q34002904-87B32AE5-CE51-46A7-8AF1-99A9F0933DE6Q34009274-E868A05A-07AA-4B8E-AC4D-FF1CB90C456AQ34527617-46EECFB1-709D-4513-AC62-553B9F26232BQ34889826-24D80ABD-C2E9-43ED-B7F7-C866E17B20DDQ35012815-A1AFC69A-2206-40C4-A033-1F99A76F2B68Q35104239-6AE72281-98D5-474C-AF6C-CE440E068D9EQ35381150-39EE1BB2-25BF-4CD6-9A96-39D40CDA7A26Q35512892-A42105D6-AA71-4F51-8422-7BB50BBB256AQ35548775-80EEC598-6B40-407C-BEFD-434DE8C7A280Q35762828-78CDCC19-7519-4AFD-AC7D-AAA1C7776696Q36099489-081A940A-52D5-4E54-A5CE-D50CCB7A954BQ36382092-F26C1C8F-AAEA-4107-B1D7-15151C736798Q36899294-10AC44BB-5971-410C-967B-E8856A32D393Q37067703-DDFDB553-0B4D-4AA2-B621-0E214AE1BA97Q37301791-ED6D0A86-CA27-4361-B5AD-15C409BE879BQ37687820-6FE5A218-C4ED-4AC4-975E-FAC64F420313Q38022246-4F3D97A9-50C0-4445-89B4-9EC80041B7A5Q38144759-AC3B540B-4620-42B0-AB6D-F41763925281
P2860
Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 1989
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Purification of Shiga toxin an ...... reactive monoclonal antibodies
@en
Purification of Shiga toxin an ...... eactive monoclonal antibodies.
@nl
type
label
Purification of Shiga toxin an ...... reactive monoclonal antibodies
@en
Purification of Shiga toxin an ...... eactive monoclonal antibodies.
@nl
prefLabel
Purification of Shiga toxin an ...... reactive monoclonal antibodies
@en
Purification of Shiga toxin an ...... eactive monoclonal antibodies.
@nl
P2093
P2860
P1476
Purification of Shiga toxin an ...... reactive monoclonal antibodies
@en
P2093
A Donohue-Rolfe
D W Acheson
G T Keusch
P2860
P304
P407
P577
1989-12-01T00:00:00Z